See analyst estimates and all valuation multiples for Regenerative Medicine
| Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| $123B | 10.9x | 56.9x | |
| $10.9B | 3.7x | 16.0x | |
| $4.3B | 12.7x | 35.0x | |
| $2.6B | 754.9x | -90.5x | |
| $2.3B | 8.9x | 21.9x | |
| $2.3B | 4.0x | 37.9x | |
| $2.0B | 8.2x | 34.7x | |
| $1.6B | 37.8x | -3.8x | |
| $1.4B | 91.6x | -30.0x | |
| $1.2B | 5.2x | 30.3x | |
| $1.0B | 15.9x | -2.4x | |
| $940M | 440.4x | -41.7x | |
| $912M | 2.6x | 11.7x | |
| $747M | 3.8x | 33.1x | |
| $579M | 1.2x | 12.0x | |
| $418M | n/a | n/a | |
| $385M | 6.9x | -0.8x | |
| $377M | 6.5x | 32.7x | |
| $362M | 11.9x | n/a | |
| $287M | n/a | n/a | |
| $283M | 22.4x | -1.2x | |
| $279M | 7.7x | -9.8x | |
| $215M | 0.7x | n/a | |
| $205M | 43.0x | -59.4x | |
| $203M | 83.5x | n/a | |
| $194M | 6.3x | -1.2x | |
| $167M | n/a | n/a | |
| $167M | 1.4x | 12.2x | |
| $137M | 5.2x | 10.8x | |
| $109M | n/a | n/a | |
| $93.7M | n/a | n/a | |
| $93.6M | 3.5x | -7.3x | |
| $87.0M | 1.8x | 55.7x | |
| $64.7M | n/a | -4.8x | |
| $56.2M | 5.6x | -2.6x | |
| $52.1M | 31.7x | n/a | |
| $35.2M | n/a | n/a | |
| $33.5M | n/a | n/a | |
| $27.3M | n/a | n/a | |
| $26.2M | n/a | n/a | |
| $19.7M | 25.2x | n/a | |
| $19.2M | 5.2x | n/a | |
| $8.4M | 1.5x | n/a | |
| $3.8M | 1.6x | n/a | |
| -$244M | -4.2x | 1.1x | |
| -$259M | -4787.8x | 1.5x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Regenerative Medicine